| Característica |
Objectiu de la convocatòria
This grant program seeks to support healthcare professionals focused on multiple myeloma (MM) in conducting research studies that generate evidence on the use of elranatamab in real‑world or clinical practice settings.
|
Característiques principals
Clinical Area: Oncology - Hematologic - RES
Projects should focus on:
Safety and efficacy of elranatamab in the context of real‑world use
Outpatient administration of elranatamab and alternative CRS/ICANS mitigation strategies
Impact of prior treatments (BsAb, ADC) on elranatamab outcomes, and wash‑out period between treatments
Clinical outcomes of elranatamab according to treatment sequencing for RRMM
Collection and assessment of PROs, caregiver burden, and treatment/prophylaxis adherence
Infection patterns, timing, types, and management strategies, including Ig replacement therapy (IV and/or SQ) while on elranatamab treatment
Assessment of elranatamab use and outcomes across patient subgroups under‑represented in clinical trials (e.g., elderly patients, those with renal impairment)
Characterizing clinical and biological determinants of response to elranatamab, including features associated with primary refractoriness, early versus delayed response, and disease relapse, as well as the identification and validation of predictive and response biomarkers
|
Lloc de presentació
HMRIB and PSMAR staff who need more information should contact:
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: [email protected] Ext.: 1670
Marta López: [email protected] Ext.: 1576
Júlia Vidal: [email protected] Ext.: 1736
|
Convocatòria (URL)
https://cdn.pfizer.com/pfizercom/2026-03/2026-ONC-RRMM-ES-RES.pdf
|
Requisits
The geographical scope is limited to Spain.
The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
Only organizations can receive grants; individuals are not eligible.
For collaborative projects, whether within a single institution or across multiple organizations, all partners must have relevant roles, and the requesting organization must play a key role.
The applicant must be the project/program lead—or an authorized designee—and must be an employee or contractor of the requesting organization.
For projects offering continuing education credit, the requesting organization must be accredited.
|
Dotació
€60,000–120,000
|
Durada
26 months, beginning in September 2026.
|